Asa Oxner, MD
Internal Medicine · Tampa, FLNPI 1275826315
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Biomerieux Inc at 59.1% of the total. 2024 is the largest year on record at $495, more than ten times the $42 reported in 2019.
Across 8 payments — averaging $79.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomerieux Inc$374
- Viiv Healthcare Company$121
- Philips North America LLC$42
- Corcept Therapeutics$23
- Johnson & Johnson$21
- Abbott$20
- plus $32 from 2 others
Across 10 payments — averaging $7496.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- BD$47K
- Sanofi US Services Inc.$28K
What the payments were for
- Food & beverage$633100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomerieux Inc | 1 | $374 |
| Viiv Healthcare Company | 1 | $121 |
| Philips North America LLC | 1 | $42 |
| Corcept Therapeutics | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Abbott | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$633 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 12 | $26,397 |
| EliquisApixaban | 30 | $21,770 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $2,109 |
| Atorvastatin Calcium | 84 | $758 |
| Buprenorphine Hcl | 13 | $748 |
| Diclofenac Sodium | 11 | $721 |
| Duloxetine Hcl | 11 | $644 |
| Omeprazole | 34 | $360 |
| Levothyroxine Sodium | 30 | $307 |
| Gabapentin | 14 | $305 |
| Losartan Potassium | 30 | $295 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $291 |
| Tamsulosin Hcl | 19 | $261 |
| Rosuvastatin Calcium | 21 | $224 |
| Pantoprazole Sodium | 17 | $219 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Tampa
- Andrew KuykendallTampa$322K
- Jhanelle GrayTampa$229K
- Anitha ReddyTampa$224K
- Benjamin CreelanTampa$212K
- Anne HermannTampa$139K
- Mark LaflammeTampa$119K
- Shahla BariTampa$56K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.